Rx Errors Up With Generic Propranolol for Hemangioma

This article originally appeared here.
Share this content:
Rx Errors Up With Generic Propranolol for Hemangioma
Rx Errors Up With Generic Propranolol for Hemangioma

FRIDAY, April 28, 2017 (HealthDay News) -- Physicians prescribing propranolol in a single concentration of 4.28 mg/mL for infantile hemangioma (IH) report fewer prescribing errors than those prescribing generic propranolol, according to a research letter published in the May issue of the Journal of the American Academy of Dermatology.

Anastasia O. Kurta, D.O., from Saint Louis University School of Medicine, and colleagues examined prescriber experience with pharmacy dispensing errors and dose calculation errors associated with generic formulations and propranolol 4.28 mg/mL. A total of 220 physicians responded to the survey, of whom 70 percent were pediatric dermatologists.

The researchers found that 90 percent of respondents reported prescribing generic propranolol and 58.6 percent reported prescribing propranolol 4.28 mg/mL. Eighteen percent of physicians reported at least one dispensing error associated with generic propranolol. Thirty percent of prescribers of generic propranolol experienced one or more dose calculation errors, made personally or by an assistant. A similar statistically significant error was reported by only 11 percent of clinicians who prescribed propranolol 4.28 mg/mL. Comparable results were reported for a subset of pediatric dermatologists. The proportion reporting one or more dose calculation errors with generic propranolol and propranolol 4.28 mg/mL was 31 and 10 percent, respectively, among prescribers with experience writing 10 to 100 prescriptions for the drug.

"If the generic formulation of propranolol is prescribed, it is important to educate caregivers to check that the label is marked with the appropriate concentration," the authors write.

Two authors disclosed financial ties to Pierre Fabre Pharmaceuticals Inc., which provided a donation for each completed survey to Pediatric Dermatology Research Alliance.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »